@article{2f4f18f29fe942748cf59dac0ff30838,
title = "Letter to the Editor: {"}Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use{"}",
keywords = "postmenopausal women, severe osteoporosis, SEVERE OSTEOPOROSIS, POSTMENOPAUSAL WOMEN",
author = "P. Geusens and F. Marin and D.L. Kendler",
note = "Funding Information: Disclosure Summary: P.G. received consultant and/or speaker fees from Lilly, and research support from Pfizer, Abbott, Lilly, Amgen, MSD, Roche, UCB, BMS, and Novartis. F.M. is an employee and a shareholder of Lilly. D.L.K. received honoraria, research grants, and/or consultant fees from Amgen, Lilly, and UCB.",
year = "2020",
month = mar,
day = "1",
doi = "10.1210/clinem/dgz122",
language = "English",
volume = "105",
pages = "E903--E904",
journal = "Journal of Clinical Endocrinology & Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "3",
}